Participating countries: 52

No. patients with 1st HCT

- 1st HCT: 18 589
- 2nd HCT: 24 520
- Total: 43 109

Re/Additional transplants

- 1st HCT: 1 217
- 2nd HCT: 3 086
- Total: 4 303

Total HCT

- 1st HCT: 19 606
- 2nd HCT: 27 606
- Total: 47 412

Myeloablative HCT (59%)

Main Indication 1st HCT

- Myeloid malignancies: 10 745
- Lymphoid malignancies: 5 127
- Solid tumours: 1 635
- Bone marrow failure: 986
- Other non-malignant disorders: 1 515
- Other: 164

Myeloid malignancies

- AML 1st CR: 4266
- not 1st CR: 1 775
- AML/MDS related changes: 1 082
- CML 1st cP: 200
- not 1st cP: 198
- MDS or MDS/MPN, MPN: 3224

Solid tumours

- Neuroblastoma: 26
- Soft tissue sarcoma/Ewing: 8
- Germ cell tumour: 2
- Other solid tumour: 15

Bone marrow failure - SAA

- Bone marrow failure - other: 266
- Thalassemia: 289
- Sickle cell disease: 324
- Primary immune deficiency: 673
- Inherited disorder of metabolism: 209
- Auto immune disease: 20
- Others: 16

Pediatric patients

- BM: 912
- PB: 410
- CB: 30
- BM: 304
- PB: 559
- CB: 801
- BM: 61
- PB: 55
- CB: 701
- BM: 0
- PB: 156
- CB: 315
- BM: 0
- PB: 0
- CB: 0

<table>
<thead>
<tr>
<th>HLA-id/twin</th>
<th>Haplo-id</th>
<th>Other relative</th>
<th>Unrelated</th>
<th>Autologous</th>
</tr>
</thead>
<tbody>
<tr>
<td>BM</td>
<td>PB</td>
<td>CB</td>
<td>BM</td>
<td>PB</td>
</tr>
<tr>
<td>912</td>
<td>410</td>
<td>30</td>
<td>304</td>
<td>559</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients with un-manipulated DLI: N=3 245.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Graft enhancement/failure: 848; residual disease: 540; relapse: 1 377; per protocol: 480.</td>
</tr>
</tbody>
</table>

Non HCT Cellular therapies used in 2021: CAR-T therapies

- Total CAR-T reported since 2018: 5 834
- Data reported from 197 centres in 24 countries.
- Notable increase of 123% since 2019 despite SAR-CoV2 pandemic.
- Other CT in 2021: 970 (MSC: 349, selected T cells: 224, other: 361).

www.ebmt.org